Manufacturer
Janssen
Contents
Ustekinumab
Indication
Moderately to severely active Crohn's disease in adult patients who had inadequate response w/, lost response to or were intolerant to either conventional therapy or a tumor necrosis factor-α (TNFα) antagonist or have medical contraindications to such therapies. Moderate to severe plaque psoriasis in adults who failed to respond to, contraindicated, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (Psoralen & UV A). Alone or in combination w/ MTX for active psoriatic arthritis when the response to previous non-biological disease-modifying anti-rheumatic drugs (DMARDs) therapy is inadequate.
Instruction
Crohn's disease Induction: Patient >85 kg 520 mg single IV infusion over at least 1 hr, >55 kg-≤85 kg 390 mg single IV infusion over at least 1 hr, ≤55 kg 260 mg single IV infusion over at least 1 hr. Maintenance: Initially 90 mg SC at wk 8 after IV dose, followed by dosing every 12 wk. Plaque psoriasis or psoriatic arthritis Initially 45 mg SC followed by 45-mg dose 4 wk later & then every 12 wk thereafter. Patient >100 kg Initially 90 mg SC followed by 90-mg dose 4 wk later & then every 12 wk thereafter.
Drug interaction
Not to be given concurrently w/ live vaccines.
Malaysia
